Core Viewpoint - The stock of药捷安康-B (02617) experienced a significant decline of over 11% during trading, closing down 9.74% at HKD 176.2, with a trading volume of HKD 591 million [1] Group 1: Company Announcement - The company announced that its board has approved the application to convert 44.9711 million domestic shares held by 10 shareholders into H-shares, which represents approximately 11.33% of the total issued shares [1] - Upon obtaining all necessary approvals and complying with applicable laws and regulations, these domestic shares will be converted into H-shares and will qualify for listing and trading on the main board of the Hong Kong Stock Exchange [1] Group 2: Market Reaction - Notably, on October 16-17, the stock rebounded strongly, with a cumulative increase of nearly 80% over two days [1] - The recent violent rebound was characterized as being driven by international short-term speculative funds, while domestic institutional investors utilized this as an "exit window" [1] - When the largest holding group not only refrains from buying but instead becomes the largest seller, the foundation of this rebound is considered to be hollow, relying entirely on subsequent follow-up buying and short-term international funds [1]
港股异动 | 药捷安康-B(02617)盘中跌超11% 公司拟H股全流通 占已发行股份总数约11.33%